OBJECTIVE: Evaluate the long-term effects of bariatric surgery on type 2 diabetes (T2DM) remission and metabolic risk factors. BACKGROUND: Although the impressive antidiabetic effects of bariatric surgery have been shown in short- and medium-term studies, the durability of these effects is uncertain. Specifically, long-term remission rates following bariatric surgery are largely unknown. METHODS: Clinical outcomes of 217 patients with T2DM who underwent bariatric surgery between 2004 and 2007 and had at least 5-year follow-up were assessed. Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood glucose (FBG) less than 100 mg/dL off diabetic medications. Changes in other metabolic comorbidities, including hypertension, dyslipidemia, and diabetic nephropathy, were assessed. RESULTS: At a median follow-up of 6 years (range: 5-9) after surgery (Roux-en-Y gastric bypass, n = 162; gastric banding, n = 32; sleeve gastrectomy, n = 23), a mean excess weight loss (EWL) of 55% was associated with mean reductions in A1C from 7.5% ± 1.5% to 6.5% ± 1.2% (P < 0.001) and FBG from 155.9 ± 59.5 mg/dL to 114.8 ± 40.2 mg/dL (P < 0.001). Long-term complete and partial remission rates were 24% and 26%, respectively, whereas 34% improved (>1% decrease in A1C without remission) from baseline and 16% remained unchanged. Shorter duration of T2DM (P < 0.001) and higher long-term EWL (P = 0.006) predicted long-term remission. Recurrence of T2DM after initial remission occurred in 19% and was associated with longer duration of T2DM (P = 0.03), less EWL (P = 0.02), and weight regain (P = 0.015). Long-term control rates of low high-density lipoprotein, high low-density lipoprotein, high triglyceridemia, and hypertension were 73%, 72%, 80%, and 62%, respectively. Diabetic nephropathy regressed (53%) or stabilized (47%). CONCLUSIONS: Bariatric surgery can induce a significant and sustainable remission and improvement of T2DM and other metabolic risk factors in severely obese patients. Surgical intervention within 5 years of diagnosis is associated with a high rate of long-term remission.
OBJECTIVE: Evaluate the long-term effects of bariatric surgery on type 2 diabetes (T2DM) remission and metabolic risk factors. BACKGROUND: Although the impressive antidiabetic effects of bariatric surgery have been shown in short- and medium-term studies, the durability of these effects is uncertain. Specifically, long-term remission rates following bariatric surgery are largely unknown. METHODS: Clinical outcomes of 217 patients with T2DM who underwent bariatric surgery between 2004 and 2007 and had at least 5-year follow-up were assessed. Complete remission was defined as glycated hemoglobin (A1C) less than 6% and fasting blood glucose (FBG) less than 100 mg/dL off diabetic medications. Changes in other metabolic comorbidities, including hypertension, dyslipidemia, and diabetic nephropathy, were assessed. RESULTS: At a median follow-up of 6 years (range: 5-9) after surgery (Roux-en-Y gastric bypass, n = 162; gastric banding, n = 32; sleeve gastrectomy, n = 23), a mean excess weight loss (EWL) of 55% was associated with mean reductions in A1C from 7.5% ± 1.5% to 6.5% ± 1.2% (P < 0.001) and FBG from 155.9 ± 59.5 mg/dL to 114.8 ± 40.2 mg/dL (P < 0.001). Long-term complete and partial remission rates were 24% and 26%, respectively, whereas 34% improved (>1% decrease in A1C without remission) from baseline and 16% remained unchanged. Shorter duration of T2DM (P < 0.001) and higher long-term EWL (P = 0.006) predicted long-term remission. Recurrence of T2DM after initial remission occurred in 19% and was associated with longer duration of T2DM (P = 0.03), less EWL (P = 0.02), and weight regain (P = 0.015). Long-term control rates of low high-density lipoprotein, high low-density lipoprotein, high triglyceridemia, and hypertension were 73%, 72%, 80%, and 62%, respectively. Diabetic nephropathy regressed (53%) or stabilized (47%). CONCLUSIONS: Bariatric surgery can induce a significant and sustainable remission and improvement of T2DM and other metabolic risk factors in severely obesepatients. Surgical intervention within 5 years of diagnosis is associated with a high rate of long-term remission.
Authors: R Caiazzo; L Arnalsteen; M Pigeyre; G Dezfoulian; H Verkindt; J Kirkby-Bott; P Mathurin; P Fontaine; M Romon; F Pattou Journal: Br J Surg Date: 2010-06 Impact factor: 6.939
Authors: Sankar D Navaneethan; Karen R Kelly; Firas Sabbagh; Philip R Schauer; John P Kirwan; Sangeeta R Kashyap Journal: Obes Surg Date: 2010-03 Impact factor: 4.129
Authors: Silas M Chikunguwo; Luke G Wolfe; Patricia Dodson; Jill G Meador; Nancy Baugh; John N Clore; John M Kellum; James W Maher Journal: Surg Obes Relat Dis Date: 2009-11-10 Impact factor: 4.734
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Rury R Holman; Sanjoy K Paul; M Angelyn Bethel; David R Matthews; H Andrew W Neil Journal: N Engl J Med Date: 2008-09-10 Impact factor: 91.245
Authors: Henry Buchwald; Rhonda Estok; Kyle Fahrbach; Deirdre Banel; Michael D Jensen; Walter J Pories; John P Bantle; Isabella Sledge Journal: Am J Med Date: 2009-03 Impact factor: 4.965
Authors: Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel Journal: Circulation Date: 2008-01-22 Impact factor: 29.690
Authors: Ralph Peterli; Bettina Wölnerhanssen; Thomas Peters; Noémie Devaux; Beatrice Kern; Caroline Christoffel-Courtin; Juergen Drewe; Markus von Flüe; Christoph Beglinger Journal: Ann Surg Date: 2009-08 Impact factor: 12.969
Authors: Lars Sjöström; Kristina Narbro; C David Sjöström; Kristjan Karason; Bo Larsson; Hans Wedel; Ted Lystig; Marianne Sullivan; Claude Bouchard; Björn Carlsson; Calle Bengtsson; Sven Dahlgren; Anders Gummesson; Peter Jacobson; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Ingmar Näslund; Torsten Olbers; Kaj Stenlöf; Jarl Torgerson; Göran Agren; Lena M S Carlsson Journal: N Engl J Med Date: 2007-08-23 Impact factor: 91.245
Authors: Ali Aminian; Amin Andalib; Maria R Ver; Ricard Corcelles; Philip R Schauer; Stacy A Brethauer Journal: Obes Surg Date: 2016-06 Impact factor: 4.129
Authors: Zhamak Khorgami; Amin Andalib; Ali Aminian; Matthew D Kroh; Philip R Schauer; Stacy A Brethauer Journal: Surg Endosc Date: 2015-08-26 Impact factor: 4.584
Authors: Tarissa Beatrice Zanata Petry; Pedro Paulo Caravatto; Fernando Quirino Pechy; Jose Luis Lopes Correia; Catia Cristina Lorenzi Guerbali; Regina Marcelina da Silva; João Eduardo Salles; Ricardo Cohen Journal: Curr Atheroscler Rep Date: 2015-09 Impact factor: 5.113
Authors: I Rasera; T H Coelho; M N Ravelli; M R M Oliveira; C V S Leite; L E Naresse; M A C A Henry Journal: Obes Surg Date: 2016-04 Impact factor: 4.129
Authors: Hazel Huang; Ali Aminian; Monique Hassan; Olivia Dan; Christopher L Axelrod; Philip R Schauer; Stacy A Brethauer; John P Kirwan Journal: Obes Surg Date: 2019-07 Impact factor: 4.129
Authors: Hinali Zaveri; Amit Surve; Daniel Cottam; Austin Cottam; Walter Medlin; Christina Richards; LeGrand Belnap; Samuel Cottam; Benjamin Horsley Journal: Obes Surg Date: 2018-10 Impact factor: 4.129